Literature DB >> 6459732

Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction.

B Rutitzky, A L Girotti, M B Rosenbaum.   

Abstract

In three patients with vasospastic angina pectoris, chronic amiodarone administered orally at doses of 800 and 1,000 mg/day totally suppressed spontaneous episodes of ischemic chest pain for 8 to 14 months. Before treatment, ergonovine maleate 0.2 to 0.4 mg intravenously provoked chest pain and similar ischemic ECG changes as those occurring spontaneously. During amiodarone treatment ergonovine vasoconstriction was totally or partially inhibited. In addition to calcium-blocking agents, amiodarone is another spasmolytic drug which effects smooth muscle relaxation by different mechanisms and appears to be useful for the chronic treatment and prevention of variant angina. The vasodilator property of amiodarone is achieved by both direct action and noncompetitive alpha receptor antagonism of coronary vasculature.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6459732     DOI: 10.1016/0002-8703(82)90526-9

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

2.  Cardiac Arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery.

Authors:  Calum A Macrae
Journal:  Expert Opin Drug Discov       Date:  2010-07       Impact factor: 6.098

Review 3.  Pathobiology and evolving therapies of coronary artery vasospasm.

Authors:  Monish A Sheth; Robert J Widmer; Hari K Dandapantula
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-04-21

4.  Effect of short and long term administration of amiodarone on ischaemia-induced left ventricular dysfunction. Implications for combined antianginal drug therapy.

Authors:  M Pfisterer; F Burkart
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

Review 5.  Treatment of coronary microvascular dysfunction.

Authors:  C Noel Bairey Merz; Carl J Pepine; Hiroki Shimokawa; Colin Berry
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 13.081

Review 6.  Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs.

Authors:  Aaron Kithcart; Calum A MacRae
Journal:  JACC Basic Transl Sci       Date:  2017-02-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.